Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

ARTIVASC 3D · Artificial vascularised scaffolds for 3D-tissue-regeneration

FP7Status: CLOSED1 November 201131 October 2015EU funding €7,800,000

The use of bioartificial tissue for regenerative medicine offers great therapeutic potential, but also has to meet high demands with respect to the interaction of the bioartificial devices and natural tissues. Key issues for the successful use of bioartifical tissues as natural tissue replacements are their long term functional stability and biocompatible integration. Up to now, various approaches for the generation of bioartificial tissues have not succeeded due to insufficient nutrition and oxygen supply. Therefore, current tissue engineered products have only been realised for non vascularised tissues such as cartilage.ArtiVasc 3D will break new ground and overcome these challenges by providing a micro- and nano-scale based manufacturing and functionalisation technology for the generation of fully vascularised bioartificial tissue that enables entire nutrition and metabolism. The bioartificial vascularised skin engineered in ArtiVasc 3D will, for the first time, allow tissue replacement with optimum properties.ArtiVasc 3D will research and develop an innovative combination of hi-tech engineering such as micro-scale printing, nano-scale multiphoton polymerisation and electro-spinning with biological research on biochemical surface modification and complex cell culture. In a multidisciplinary approach, experts in biomaterial development, cell-matrix interaction, angiogenesis, tissue engineering, simulation, design and fabrication methods work together to generate bioartificial vascularised skin in a fully automated and standardised manufacturing approach.This bioartificial vascularised skin will be of great value in a vast array of clinical treatments, e.g. as a transplant in trauma treatment. In addition, this new bioartificial vascularised skin will be used as an innovative in vitro skin equivalent for pharmaceutical, cosmetics or chemical substance testing, which represents a promising method to reduce expensive, ethically disputed animal testing.

Consortium · 17 organisations

coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €2,207,375

participant

MEDIZINISCHE UNIVERSITAET WIEN

AT · €426,607

participant

UNIVERSITY OF EAST ANGLIA

UK · €461,029

participant

UNIVERSITA DEGLI STUDI DI SALERNO

IT · €374,999

participant

VEREIN ZUR FORDERUNG VON INNOVATIONEN DURCH FORSCHUNG ENTWICKLUNG UNDTECHNOLOGIETRANSFER EV

DE · €499,316

participant

AO-FORSCHUNGSINSTITUT DAVOS

CH · €90,054

participant

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

DE · €309,779

participant

AALTO KORKEAKOULUSAATIO SR

FI · €444,730

participant

UNITECHNOLOGIES SA

CH · €528,562

participant

VIMECON GMBH

DE · €148,307

participant

BEIERSDORF AG

DE · €363,678

participant

ARTTIC

FR · €377,632

participant

KMS Automation GmbH

DE · €374,999

participant

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

DE · €444,317

participant

LOUGHBOROUGH UNIVERSITY

UK · €328,877

participant

UNIVERSITY OF STUTTGART

DE · €419,740

participant

GLOBAL CLINICAL TRIALS MANAGEMENT AG

CH

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.